Advanced in Enlarged Prostate (BPH)

Peter Schatteman

AZ Sint Jan Brugge Oostende AV
Brugge, VLG, BE 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Enlarged Prostate (BPH)
AZ Sint Jan Brugge Oostende AV
Brugge, VLG, BE 
OverviewLocationsClinical Research

Overview

Peter Schatteman practices in Brugge, Belgium. Mr. Schatteman is rated as an Advanced expert by MediFind in the treatment of Enlarged Prostate (BPH). His top areas of expertise are Enlarged Prostate (BPH), Prostate Cancer, Bladder Cancer, Prostatectomy, and Nephrectomy.

His clinical research consists of co-authoring 48 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Enlarged Prostate (BPH).

Gender
Male

Locations

AZ Sint Jan Brugge Oostende AV
Brugge, VLG, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Enrollment Status: Recruiting
Publish Date: May 01, 2025
Intervention Type: Genetic
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer
A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2024
Intervention Type: Other, Radiation, Drug
Study Drugs: Abiraterone acetate, Docetaxel
Study Phase: Phase 3
View 2 Less Clinical Trial

48 Total Publications

Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?
Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?
Journal: Acta oncologica (Stockholm, Sweden)
Published: May 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schatteman's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile